BAYER AG
🇩🇪Germany
- Country
- 🇩🇪Germany
- Ownership
- Public
- Established
- 1863-08-01
- Employees
- 99.7K
- Market Cap
- $30.1B
- Website
- http://www.bayer.com
Safety and Efficacy of BAY1192631 in Japanese Patients With Methicillin-resistant Staphylococcus Aureus (MRSA) Infections
Phase 3
Completed
- Conditions
- Skin Diseases, Infectious
- Interventions
- First Posted Date
- 2013-10-22
- Last Posted Date
- 2018-10-04
- Lead Sponsor
- Bayer
- Target Recruit Count
- 125
- Registration Number
- NCT01967225
Study to Assess the Dietary Carbohydrate Content of Indian Diabetics With Special Therapeutic View on Effectiveness of Acarbose and Metformin Monotherapy
- First Posted Date
- 2013-10-11
- Last Posted Date
- 2016-06-15
- Lead Sponsor
- Bayer
- Registration Number
- NCT01961388
MIRENA for Contraception In InDian Subjects User continuAtion and Satisfaction Study: MIDAS Study
Completed
- Conditions
- Contraception
- Interventions
- Drug: Levonorgestrel- Intra Uterine System (BAY 86-5028_Mirena)
- First Posted Date
- 2013-10-11
- Last Posted Date
- 2023-10-13
- Lead Sponsor
- Bayer
- Target Recruit Count
- 600
- Registration Number
- NCT01961375
Investigating the Use of Regorafenib (Stivarga®) in Patients With Metastatic Colorectal Cancer (mCRC) After Failure of Standard Therapy
- First Posted Date
- 2013-10-09
- Last Posted Date
- 2018-03-08
- Lead Sponsor
- Bayer
- Target Recruit Count
- 483
- Registration Number
- NCT01959269
Bleeding Pattern Difference Between Levonorgestrel Intrauterine System (LNG-IUS) and Copper Intrauterine Devices (IUDs) Immediately Inserted After Abortion
Completed
- Conditions
- Contraception
- Interventions
- Drug: Levonorgestrel IUS (Mirena, BAY86-5028)Device: Copper-IUD
- First Posted Date
- 2013-10-09
- Last Posted Date
- 2015-10-16
- Lead Sponsor
- Bayer
- Target Recruit Count
- 512
- Registration Number
- NCT01958684
Fosrenol Post-marketing Surveillance in Japan
Completed
- Conditions
- HyperphosphatemiaKidney Disease
- Interventions
- Drug: Lanthanum Carbonate (Fosrenol, BAY77-1931)
- First Posted Date
- 2013-10-08
- Last Posted Date
- 2018-02-23
- Lead Sponsor
- Bayer
- Target Recruit Count
- 343
- Registration Number
- NCT01955876
Phase IIb Safety and Efficacy Study of BAY94-8862 in Subjects With Worsening Chronic Heart Failure and Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Moderate Chronic Kidney Disease Alone
- First Posted Date
- 2013-10-07
- Last Posted Date
- 2021-07-16
- Lead Sponsor
- Bayer
- Target Recruit Count
- 72
- Registration Number
- NCT01955694
Phase IIb Safety and Efficacy Study of Four Dose Regimens of BAY1021189 in Patients With Heart Failure With Reduced Ejection Fraction Suffering From Worsening Chronic Heart Failure (SOCRATES-REDUCED)
Phase 2
Completed
- Conditions
- Heart Failure
- Interventions
- First Posted Date
- 2013-09-26
- Last Posted Date
- 2021-03-25
- Lead Sponsor
- Bayer
- Target Recruit Count
- 456
- Registration Number
- NCT01951625
- Locations
- 🇨🇿
Fakultni nemocnice Ostrava, Ostrava, Czechia
Phase IIb Safety and Efficacy Study of Four Dose Regimens of BAY1021189 in Patients With Heart Failure and Preserved Ejection Fraction Suffering From Worsening Chronic Heart Failure (SOCRATES-PRESERVED)
Phase 2
Completed
- Conditions
- Heart Failure
- Interventions
- First Posted Date
- 2013-09-26
- Last Posted Date
- 2021-03-16
- Lead Sponsor
- Bayer
- Target Recruit Count
- 477
- Registration Number
- NCT01951638
Efficacy/Safety Study to Explore a New Revised Topical Formulation in Atopic Dermatitis
Not Applicable
Completed
- Conditions
- Dermatitis, Atopic
- Interventions
- Device: Phoenix II (BAY81-2996)Device: Phoenix I (BAY81-2996)
- First Posted Date
- 2013-09-24
- Last Posted Date
- 2014-08-07
- Lead Sponsor
- Bayer
- Target Recruit Count
- 35
- Registration Number
- NCT01948869
© Copyright 2025. All Rights Reserved by MedPath